Search

Displaying results 1131 - 1140 of 2440 in total
  1. Drug

    Binimetinib

    go.drugbank.com/drugs/DB11967
    ApprovedInvestigational

    Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib. On June 27, 2018, the Food and Drug Administration approved the combination o...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  2. Drug

    Ponesimod

    go.drugbank.com/drugs/DB12016
    ApprovedInvestigational

    Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-ph...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Lorvotuzumab mertansine

    go.drugbank.com/drugs/DB12089
    Investigational

    Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  4. Drug

    Secoisolariciresinol

    go.drugbank.com/drugs/DB12179
    Investigational

    Secoisolariciresinol has been used in trials studying the prevention of Breast Cancer.

    Categories: P-glycoprotein inhibitors
  5. Drug

    Estetrol

    go.drugbank.com/drugs/DB12235
    ApprovedInvestigational

    Naturally or synthetically produced steroid estrogens have a wide range of pharmaceutical uses ranging from hormonal contraception to the treatment of menopausal symptoms. Estetrol (E4) is a native estrogen occurring naturally during pre...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by T. brucei gambiense and T. brucei rhodesiense, remains a moderate risk (>1/10,000 inhabitants per year in endemic areas) despite focuss...

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates
  7. Drug

    Epofolate

    go.drugbank.com/drugs/DB12266
    Investigational

    Epofolate has been used in trials studying the treatment of Advanced Solid Tumors. Epofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to selectively target folate receptor expressing cancer...

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  8. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab. Aducanumab is a recombinant antibody derived from patients with slow ...

  9. Drug

    Lynestrenol

    go.drugbank.com/drugs/DB12474
    ApprovedWithdrawn

    Lynestrenol is a progestin and prodrug of norethisterone.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Ethyl biscoumacetate

    go.drugbank.com/drugs/DB08794
    ApprovedWithdrawn

    Ethyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates